Previous 10 | Next 10 |
2023-05-04 17:27:20 ET NGM Biopharmaceuticals press release ( NASDAQ: NGM ): Q1 GAAP EPS of -$0.58 misses by $0.06 . Revenue of $2.25M (-89.3% Y/Y) misses by $3.89M . Cash, cash equivalents and short-term marketable securities were $231.0 million as of March...
Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product ca...
2023-04-04 17:43:11 ET NGM Biopharmaceuticals ( NASDAQ: NGM ) on Tuesday said it would cut about 33% of its workforce. The company in a regulatory filing said its headcount would be reduced by 75 people and that it expects to incur about $5M in restructuring charges. N...
2023-03-22 07:44:35 ET Liver disease drug developer 89bio ( NASDAQ: ETNB ) added ~47% on Wednesday after announcing topline data from its Phase 2b ENLIVEN trial for pegozafermin in patients with nonalcoholic steatohepatitis (NASH). The trial involved 219 patients who wer...
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, wi...
NGM Biopharmaceuticals press release ( NASDAQ: NGM ): Q4 GAAP EPS of -$0.45 beats by $0.07 . Revenue of $18.18M (-13.3% Y/Y) beats by $11.56M . Cash, cash equivalents and short-term marketable securities were $271.5 million as of December 31, 2022, compared to $36...
--Presented preliminary findings from the Phase 1a monotherapy dose escalation portion of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the ESMO I-O Annual Congress-- --Initiated a Phase 1b cohort of the ongoing Phase 1/1b trial evaluating...
Summary NGM failed both the NASH and GA trials. However, its oncology pipeline looks promising. The company has some cash for survival. For further details see: NGM Biopharmaceuticals: A Double Whammy Of NASH And GA Failure Hurt Its Stock
Column Group buys $1.5M shares in NGM Biopharmaceuticals ( NASDAQ: NGM ) as of January 10, 2023. The stock jumped 14% during after market hours trading at $5.75. Column Group had purchased 309,070 shares of company stock at $4.79 per share between January 10 and January 11 for...
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and...
News, Short Squeeze, Breakout and More Instantly...
NGM Biopharmaceuticals Inc. Company Name:
NGM Stock Symbol:
NYSE Market:
NGM Biopharmaceuticals Inc. Website:
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an...
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongo...
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 202...